Malignant astrocytic glioma: genetics, biology, and paths to treatment
Open accessAbstract
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death. The recent confluence of advances in stem cell biology, cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biology and clinical behavior of glioblastoma. This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clinical responses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
EGFR amplification and EGFRvIII activating mutation are the most common oncogenes promoting PI3K signaling in GBM.
“EGFR amplification, and EGFRvIII activating mutation are the most common oncogenes promoting PI3K signaling in GBM (1, 6).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · see citing works
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862 · see citing works
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · see citing works
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · see citing works
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · see citing works
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · see citing works
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · see citing works
Self-citationRescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 2× · see citing works
“The second protein encoded by CDKN2A, p14 ARF , was subsequently shown to be an important accessory to p53 activation under conditions of oncogenic stress due to its neutralization of the p53 ubiquitin ligase, MDM2 (Ka-mijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Honda and Yasuda 1999), an oncogene orig…”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1× · see citing works
“…cell line, and then later found to be a key negative regulator of p53 during normal development and in tumorigenesis (Fakharzadeh et al. 1991; Momand et al. 1992; Oliner et al. 1993; Jones et al. 1995; Montes de Oca Luna et al. 1995; Honda et al. 1997; Fang et al. 2000; Honda and Yasuda 2000).”
BackgroundIncreasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing
Molofsky, A. V., Slutsky, S. G., Joseph, N. M., He, S., Pardal, R., Krishnamurthy, J., Sharpless, N. E., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature05091 · Cited by 972 · cited 1× · see citing works
“Consistent with its role as an important glioma tumor suppressor, p16 Ink4a is also a critical inhibitor of progenitor cell renewal in the sub-ventricular zone of aging mice (Molofsky et al. 2006).”
BackgroundYung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 1× · see citing works
“In comparison, TMZ given at first recurrence in GBM yields a PFS6 of 21% (Yung et al. 2000).”
BackgroundFunctional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899 · see citing works
Ubiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748 · see citing works
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724 · see citing works
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · see citing works
Signalling through Class I PI3Ks in mammalian cells
Hawkins, P. T., Anderson, K. E., Davidson, K., & Stephens, L. R. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340647 · Cited by 540 · see citing works
A negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501 · see citing works
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465 · see citing works
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361 · see citing works
Flagged first, then by citations
Research works printed but not linked: 32
- Ahn, J.Y., Hu, Y., Kroll, T.G., Allard, P., and Ye, K. 2004. PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt. Proc. Natl. Acad. Sci. 101: 6993-6998.
- Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. 2003. Prospective identification of tumori- genic breast cancer cells. Proc. Natl. Acad. Sci. 100: 3983- 3988.
- Hegi, M.E., Murat, A., Lambiv, W.L., and Stupp, R. 2006. Brain tumors: Molecular biology and targeted therapies. Ann. On- col. 17 (Suppl. 10): x191-x197. doi: 10.1093/annonc/mdl259. · DOI
- Hemmati, H.D., Nakano, I., Lazareff, J.A., Masterman-Smith, M., Geschwind, D.H., Bronner-Fraser, M., and Kornblum, H.I. 2003. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. 100: 15178-15183.
- Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A.J., and Ott, J. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. 99: 8467-8472.
- Horvath, S., Zhang, B., Carlson, M., Lu, K.V., Zhu, S., Felciano, R.M., Laurance, M.F., Zhao, W., Qi, S., Chen, Z., et al. 2006. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc. Natl. Acad. Sci. 103: 17402-17407.
- Hu, B., Guo, P., Fang, Q., Tao, H.Q., Wang, D., Nagane, M., Huang, H.J., Gunji, Y., Nishikawa, R., Alitalo, K., et al. 2003. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc. Natl. Acad. Sci. 100: 8904-8909.
- Huang, H.S., Nagane, M., Klingbeil, C.K., Lin, H., Nishikawa, R., Ji, X.D., Huang, C.M., Gill, G.N., Wiley, H.S., and Cave- nee, W.K. 1997. The enhanced tumorigenic activity of a mu- tant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyro- sine phosphorylation and unattenuated signaling. J. Biol. Chem. 272: 2927-2935.
- Huang, P.H., Mukasa, A., Bonavia, R., Flynn, R.A., Brewer, Z.E., Cavenee, W.K., Furnari, F.B., and White, R. 2007. Quantita- tive analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. 104: 12867-12872.
- Jungbluth, A.A., Stockert, E., Huang, H.J., Collins, V.P., Coplan, K., Iversen, K., Kolb, D., Johns, T.J., Scott, A.M., Gullick, W.J., et al. 2003. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl. Acad. Sci. 100: 639-644.
- Kang, S., Denley, A., Vanhaesebroeck, B., and Vogt, P.K. 2006. Oncogenic transformation induced by the p110, -␥, and -␦ isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. 103: 1289-1294.
- Kilic, T., Alberta, J.A., Zdunek, P.R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P.M., and Stiles, C.D. 2000. Intracranial inhibition of platelet-derived growth fac- tor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Can- cer Res. 60: 5143-5150.
- Lee, J.C., Vivanco, I., Beroukhim, R., Huang, J.H., Feng, W.L., DeBiasi, R.M., Yoshimoto, K., King, J.C., Nghiemphu, P., Yuza, Y., et al. 2006. Epidermal growth factor receptor acti- vation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 3: e485. doi: 10.1371/ journal.pmed.0030485. · DOI
- Liang, Y., Diehn, M., Watson, N., Bollen, A.W., Aldape, K.D., Nicholas, M.K., Lamborn, K.R., Berger, M.S., Botstein, D., Brown, P.O., et al. 2005. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. 102: 5814-5819.
- Louis, D.N. and Cavenee, W. 1997. Molecular biology of central nervous system neoplasms. In Cancer: Principles and prac- tice of oncology (eds. V.T. Devita and S. Hellman), pp. 2013- 2022. Lippincott-Raven, Philadelphia.
- Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, B.W., and Kleihues, P., eds. 2007. The 2007 WHO classification of tumours of the cen- tral nervous system. IARC Press, Lyon, France.
- Nagane, M., Levitzki, A., Gazit, A., Cavenee, W.K., and Huang, H.J. 1998. Drug resistance of human glioblastoma cells con- ferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. 95: 5724-5729.
- Nishikawa, R., Ji, X.D., Harmon, R.C., Lazar, C.S., Gill, G.N., Cavenee, W.K., and Huang, H.J. 1994. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. 91: 7727- 7731.
- Passegue, E., Jamieson, C.H., Ailles, L.E., and Weissman, I.L. 2003. Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell character- istics? Proc. Natl. Acad. Sci. 100 (Suppl. 1): 11842-11849. doi: 10.1073/pnas.2034201100. · DOI
- Prados, M., Chang, S., Burton, E., Kapadia, A., Rabbitt, J., Page, M., Federoff, A., Kelly, S., Fyfe, G. 2003. Phase I study of OSI-774 alone or with temozolomide in patients with ma- lignant glioma. Proc. Am. Soc. Clin. Oncol. 22: 99.
- Prince, M.E., Sivanandan, R., Kaczorowski, A., Wolf, G.T., Kaplan, M.J., Dalerba, P., Weissman, I.L., Clarke, M.F., and Ailles, L.E. 2007. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. 104: 973-978.
- Raza, S.M., Lang, F.F., Aggarwal, B.B., Fuller, G.N., Wildrick, D.M., and Sawaya, R. 2002. Necrosis and glioblastoma: A friend or a foe? A review and a hypothesis. Neurosurgery 51: 2-12.
- Sakariassen, P.O., Prestegarden, L., Wang, J., Skaftnesmo, K.O., Mahesparan, R., Molthoff, C., Sminia, P., Sundlisaeter, E., Misra, A., Tysnes, B.B., et al. 2006. Angiogenesis-indepen- dent tumor growth mediated by stem-like cancer cells. Proc. Natl. Acad. Sci. 103: 16466-16471.
- Scott, A.M., Lee, F.T., Tebbutt, N., Herbertson, R., Gill, S.S., Liu, Z., Skrinos, E., Murone, C., Saunder, T.H., Chappell, B., et al. 2007. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl. Acad. Sci. 104: 4071- 4076.
- Song, S.W., Fuller, G.N., Khan, A., Kong, S., Shen, W., Taylor, E., Ramdas, L., Lang, F.F., and Zhang, W. 2003. IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) bind- ing protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc. Natl. Acad. Sci. 100: 13970-13975.
- Stewart, L.A. 2002. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018.
- Stommel, J.M., Kimmelman, A.C., Ying, H., Nabioullin, R., Ponugoti, A.H., Wiedemeyer, R., Stegh, A.H., Bradner, J.E., Ligon, K.L., Brennan, C., et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to tar- geted therapies. Science doi: 10.1126/science.1142946. · DOI · Paper page
- Sugawa, N., Ekstrand, A.J., James, C.D., and Collins, V.P. 1990. Identical splicing of aberrant epidermal growth factor recep- tor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. 87: 8602-8606.
- Wiley, S.R. and Winkles, J.A. 2003. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 14: 241-249.
- Wong, A.J., Ruppert, J.M., Bigner, S.H., Grzeschik, C.H., Hum- phrey, P.A., Bigner, D.S., and Vogelstein, B. 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. 89: 2965-2969.
- You, H., Jang, Y., You-Ten, A.I., Okada, H., Liepa, J., Wakeham, A., Zaugg, K., and Mak, T.W. 2004. p53-dependent inhibi- tion of FKHRL1 in response to DNA damage through protein kinase SGK1. Proc. Natl. Acad. Sci. 101: 14057-14062.
- You, H., Yamamoto, K., and Mak, T.W. 2006. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc. Natl. Acad. Sci. 103: 9051-9056.
Cited by
Sorted by citations
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · see citing works
Self-citation<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · see citing works
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · see citing works
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · see citing works
Glioma-Derived Mutations in <i>IDH1</i> Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · see citing works
Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025 · see citing works
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis
Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W. K., & Lu, Z. (2012) · Cell · doi:10.1016/j.cell.2012.07.018 · Cited by 846 · see citing works
Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813 · see citing works
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767 · see citing works
Self-citationAlcantara Llaguno, S., Chen, J., Kwon, C.-H., Jackson, E. L., Li, Y., Burns, D. K., Alvarez-Buylla, A., & Parada, L. F. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.006 · Cited by 694 · see citing works
Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A. N., Soto, H., Zhu, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0102 · Cited by 452 · see citing works
“org Correction: An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/ LDLR–Dependent Pathway In this article (Cancer Discovery 2011;1:442–56), which was published in the October 2011 issue of Cancer Discovery (1), the following errors appear in the Results section.”
BackgroundInfluential<i>EGFR</i> Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Francis, J. M., Zhang, C.-Z., Maire, C. L., Jung, J., Manzo, V. E., Adalsteinsson, V. A., Homer, H., Haidar, S., Blumenstiel, B., Pedamallu, C. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0879 · Cited by 287 · see citing works
Self-citationJi, H., Wang, J., Nika, H., Hawke, D., Keezer, S., Ge, Q., Fang, B., Fang, X., Fang, D., Litchfield, D. W., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.034 · Cited by 270 · see citing works
Novel Oncogenic <i>PDGFRA</i> Mutations in Pediatric High-Grade Gliomas
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., Bax, D. A., Carvalho, D., Reis, R. M., Onar-Thomas, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1491 · Cited by 235 · see citing works
Molecular and Genomic Alterations in Glioblastoma Multiforme
Crespo, I., Vital, A. L., Gonzalez-Tablas, M., Patino, M. D. C., Otero, A., Lopes, M. C., de Oliveira, C., Domingues, P., Orfao, A., & Tabernero, M. D. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.02.023 · Cited by 225 · see citing works
Yan, F., Alinari, L., Lustberg, M. E., Katherine Martin, L., Cordero-Nieves, H. M., Banasavadi-Siddegowda, Y., Virk, S., Barnholtz-Sloan, J., Bell, E. H., Wojton, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0884 · Cited by 180 · see citing works
Shingu, T., Fujiwara, K., Bögler, O., Akiyama, Y., Moritake, K., Shinojima, N., Tamada, Y., Yokoyama, T., & Kondo, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24030 · Cited by 174 · see citing works
PARP-1 protein expression in glioblastoma multiforme
Galia, A., Calogero, A. E., Condorelli, R., Fraggetta, F., La Corte, A., Ridolfo, F., Bosco, P., Castiglione, R., & Salemi, M. (2012) · European Journal of Histochemistry · doi:10.4081/ejh.2012.e9 · Cited by 145 · see citing works
DINGO: differential network analysis in genomics
Ha, M. J., Baladandayuthapani, V., & Do, K.-A. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv406 · Cited by 120 · see citing works
mTOR-Dependent Cell Proliferation in the Brain
Ryskalin, L., Lazzeri, G., Flaibani, M., Biagioni, F., Gambardella, S., Frati, A., & Fornai, F. (2017) · BioMed Research International · doi:10.1155/2017/7082696 · Cited by 86 · see citing works
Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072281 · Cited by 79 · see citing works
Neutralization of terminal differentiation in gliomagenesis
Hu, J., Ho, A. L., Yuan, L., Hu, B., Hua, S., Hwang, S. S., Zhang, J., Hu, T., Zheng, H., Gan, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308610110 · Cited by 76 · see citing works
Self-citationLewerenz, J., Baxter, P., Kassubek, R., Albrecht, P., Van Liefferinge, J., Westhoff, M.-A., Halatsch, M.-E., Karpel-Massler, G., Meakin, P. J., Hayes, J. D., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5455 · Cited by 66 · see citing works
Gao, H., Chu, C., Cheng, Y., Zhang, Y., Pang, X., Li, D., Wang, X., Ren, E., Xie, F., Bai, Y., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c03873 · Cited by 59 · see citing works
Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model
Fahey, J. M., Emmer, J. V., Korytowski, W., Hogg, N., & Girotti, A. W. (2016) · Photochemistry and Photobiology · doi:10.1111/php.12636 · Cited by 49 · see citing works
Wisniewski, P., Ellert-Miklaszewska, A., Kwiatkowska, A., & Kaminska, B. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.09.016 · Cited by 46 · see citing works
Skała, E., Kowalczyk, T., Toma, M., Szemraj, J., Radek, M., Pytel, D., Wieczfinska, J., Wysokińska, H., Śliwiński, T., & Sitarek, P. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3254-z · Cited by 18 · see citing works
Mantile, F., Kisovec, M., Adamo, G., Romancino, D. P., Hočevar, M., Božič, D., Bedina Zavec, A., Podobnik, M., Stoppelli, M. P., Kisslinger, A., et al. (2022) · Cancers · doi:10.3390/cancers14153700 · Cited by 18 · see citing works
- Authors
- Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., Chin, L., DePinho, R. A., & Cavenee, W. K.
- Affiliations
- University of California San Diego (US)
- The University of Texas Southwestern Medical Center (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2007-11-01
- Volume
- 21
- Issue
- 21
- Pages
- 2683-2710
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2151335185
- Cited by
- 2,316
- References
- 22
- Citations by year
- 2026: 32 · 2025: 55 · 2024: 67 · 2023: 77 · 2022: 79 · 2021: 133 · 2020: 122 · 2019: 129 · 2018: 157 · 2017: 150 · 2016: 148 · 2015: 189 · 2014: 158 · 2013: 173 · 2012: 154
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (acceptedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Ellison Medical Foundation
- V Foundation for Cancer Research
- National Foundation for Cancer Research
- National Cancer Institute (CA 95616, R01CA099041, P01CA095616, CA099041)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- glioblastoma, cancer genetics, tumor biology, tumor invasion, drug resistance, targeted therapy, stem cell biology, signal transduction, new drugs
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Astrocytoma, Brain Neoplasms, Disease Models, Animal, Humans, Models, Biological, Necrosis, Neoplasm Invasiveness, Neoplasm Staging, Neovascularization, Pathologic, Animals, Genetically Modified, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
